BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Mallinckrodt
Medtronic
Boehringer Ingelheim
Covington
Colorcon
Harvard Business School
Cipla
Argus Health
Daiichi Sankyo

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,157,456

« Back to Dashboard

Summary for Patent: 7,157,456
Title:Substituted oxazolidinones and their use in the field of blood coagulation
Abstract: The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) ##STR00001## processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
Inventor(s): Straub; Alexander (Wuppertal, DE), Lampe; Thomas (Wuppertal, DE), Pohlmann; Jens (Wuppertal, DE), Rohrig; Susanne (Essen, DE), Perzborn; Elisabeth (Wuppertal, DE), Schlemmer; Karl-Heinz (Wuppertal, DE), Pernerstorfer; Joseph (Wuppertal, DE)
Assignee: Bayer HealthCare AG (Leverkusen, DE)
Application Number:10/181,051
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Use;

Drugs Protected by US Patent 7,157,456

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF DEEP VEIN THROMBOSIS (DVT) ➤ Subscribe
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-001 Jul 1, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF PULMONARY EMBOLISM (PE) ➤ Subscribe
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-002 Nov 4, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF DEEP VEIN THROMBOSIS (DVT) ➤ Subscribe
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-002 Nov 4, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF PULMONARY EMBOLISM (PE) ➤ Subscribe
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-003 Nov 4, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF DEEP VEIN THROMBOSIS (DVT) ➤ Subscribe
Janssen Pharms XARELTO rivaroxaban TABLET;ORAL 022406-003 Nov 4, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF PULMONARY EMBOLISM (PE) ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,157,456

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany199 62 924Dec 24, 1999
PCT Information
PCT FiledDecember 11, 2000PCT Application Number:PCT/EP00/12492
PCT Publication Date:July 05, 2001PCT Publication Number: WO01/47919

Non-Orange Book US Patents Family Members for Patent 7,157,456

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,530,505 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Subscribe
7,576,111 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Subscribe
7,585,860 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Subscribe
8,822,458 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Subscribe
8,129,378 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Subscribe
7,592,339 Substituted oxazolidinones and their use in the field of blood coagulation ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,157,456

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I277615 ➤ Subscribe
Taiwan 200422299 ➤ Subscribe
Taiwan I226330 ➤ Subscribe
Turkey 200401314 ➤ Subscribe
Turkey 200201636 ➤ Subscribe
El Salvador 2002000245 ➤ Subscribe
Slovakia 287272 ➤ Subscribe
Slovakia 9082002 ➤ Subscribe
Slovenia 1526132 ➤ Subscribe
Slovenia 1261606 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Healthtrust
Queensland Health
Cipla
Johnson and Johnson
Baxter
Chubb
Julphar
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot